Head to Head Contrast: Mindray Medical International (MR) and IRIDEX Corporation (IRIX)

Mindray Medical International (NYSE: MR) and IRIDEX Corporation (NASDAQ:IRIX) are both companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

47.9% of IRIDEX Corporation shares are owned by institutional investors. 5.0% of IRIDEX Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Mindray Medical International and IRIDEX Corporation’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Mindray Medical International N/A N/A N/A $1.49 18.75
IRIDEX Corporation $46.16 million 1.91 -$11.71 million ($1.71) -4.46

Mindray Medical International has higher revenue, but lower earnings than IRIDEX Corporation. IRIDEX Corporation is trading at a lower price-to-earnings ratio than Mindray Medical International, indicating that it is currently the more affordable of the two stocks.

Dividends

Mindray Medical International pays an annual dividend of $0.36 per share and has a dividend yield of 1.3%. IRIDEX Corporation does not pay a dividend. Mindray Medical International pays out 24.2% of its earnings in the form of a dividend.

Profitability

This table compares Mindray Medical International and IRIDEX Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mindray Medical International 15.93% 12.70% 8.37%
IRIDEX Corporation -42.22% -23.21% -19.03%

Analyst Ratings

This is a breakdown of current ratings and target prices for Mindray Medical International and IRIDEX Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mindray Medical International 0 0 0 0 N/A
IRIDEX Corporation 0 0 1 0 3.00

IRIDEX Corporation has a consensus price target of $13.00, suggesting a potential upside of 70.38%. Given IRIDEX Corporation’s higher probable upside, analysts plainly believe IRIDEX Corporation is more favorable than Mindray Medical International.

Summary

IRIDEX Corporation beats Mindray Medical International on 6 of the 11 factors compared between the two stocks.

About Mindray Medical International

Mindray Medical International Limited is a developer, manufacturer and marketer of medical devices across the world. The Company operates in three segments: patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. Its patient monitoring devices track the physiological parameters of patients, such as heart rate, blood pressure, respiration and temperature. It offers patient monitoring devices that are suitable for adult, pediatric and neonatal patients and are used principally in hospital intensive care units, operating rooms and emergency rooms. Its life support products provide operation room or intensive care unit solutions for the end users in the operating room. Its in-vitro diagnostic products provide data and analysis on blood, urine and other bodily fluid samples for clinical diagnosis and treatment. Its medical imaging systems segment includes ultrasound systems, digital radiography systems and a magnetic resonance imaging system.

About IRIDEX Corporation

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Receive News & Ratings for Mindray Medical International Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mindray Medical International Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply